BD Secures FDA Clearance for EnCor EnCompass™ System
The EnCor EnCompass™ Breast Biopsy and Tissue Removal System by BD, also known as Becton, Dickinson and Company (NYSE: BDX), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This advanced system is set to revolutionize breast biopsies, providing enhanced flexibility across different breast imaging modalities for accurate disease detection.
A Leap Forward in Breast Health Technology
The impending launch of the EnCor EnCompass™ system is a significant achievement in breast health technology. Rima Alameddine, the worldwide president of Peripheral Intervention at BD, emphasized that this development exemplifies their dedication to improving breast disease diagnosis. With the system expected to hit the market in early 2026, it aims to set new standards in patient-centric healthcare.
Enhanced User Experience and Efficiency
This innovative biopsy system is designed with clinicians in mind, allowing them to perform procedures across various breast imaging platforms seamlessly and efficiently. Stacie Watson, the vice president and general manager of the Oncology Platform at BD Interventional, expressed that the FDA clearance highlights BD's consistent focus on meeting the evolving demands of healthcare providers and patients.
Notable Features of the EnCor EnCompass™ System
Some of the key features that make the EnCor EnCompass™ Breast Biopsy System stand out include:
- Support for multiple modalities, enhancing the versatility of biopsy procedures.
- Adjustable vacuum strengths accompanied by a variable sample notch for customized procedures.
- 360° sampling capabilities for comprehensive access to lesions located throughout the breast.
- Advanced visualization tools, including an echogenic cutting cannula and illuminated sample container.
- Probes available in various sizes (12G, 10G, and 7G) to suit different lesion types and locations.
Expert Insights on the Biopsy System
Dr. Shadi Aminololama-Shakeri, M.D., Chief of Breast Radiology at a leading medical center, remarked that this system represents a commitment to delivering the highest quality of care for patients while optimizing the biopsy process for clinicians. The combination of advanced features signifies a major leap forward in biopsy technology.
Commitment to Breast Health Innovation
The introduction of the EnCor EnCompass™ system signifies BD's ongoing commitment to expanding its breast health portfolio. This clearance not only reflects the company's strategic focus on early detection and diagnosis of breast disease, but it also aligns with their mission to innovate within the healthcare sector, ensuring better outcomes for patients.
Looking Ahead: The Future of Breast Biopsy Technology
With the EnCor EnCompass™ system expected to launch in early 2026, BD is positioning itself as a leader in healthcare innovation. The combination of user-friendly design and high-performance capabilities ensures that clinicians will have the tools necessary to improve patient care pathways effectively.
About BD
BD is a prominent global medical technology company known for advancing the world of health. With a workforce of over 70,000 dedicated employees, BD is committed to improving medical discoveries, diagnostics, and the overall delivery of care. They focus on developing innovative technologies and solutions that both enhance clinical therapy for patients and streamline processes for healthcare providers. BD partners globally to tackle some of the most pressing health challenges and continuously strives to enhance outcomes and expand access to healthcare.
Frequently Asked Questions
What is the EnCor EnCompass™ Breast Biopsy System?
The EnCor EnCompass™ Breast Biopsy and Tissue Removal System is an advanced tool designed for breast biopsies, enhancing diagnostic capabilities across various imaging platforms.
When is the EnCor system expected to be available?
The EnCor EnCompass™ Breast Biopsy System is expected to enter the market in early 2026.
What features does the EnCor system offer for clinicians?
The system includes multi-modality support, customizable vacuum strengths, 360° sampling, and advanced visualization tools to enhance the biopsy experience.
What company is behind the EnCor EnCompass™ system?
The system is developed by BD (Becton, Dickinson and Company), a leader in medical technology.
How does this system improve patient care?
By streamlining the biopsy process and enhancing diagnostic accuracy, the EnCor system ultimately supports better patient outcomes in breast health.
